DDInter1860 DDInter997
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Triazolam {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Triazolam {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Triazolam {u} (Compound) resembles {v} (Compound) Clonazepam
Clonazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Triazolam {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Triazolam {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Triazolam {u} (Compound) resembles {v} (Compound) Clonazepam
Clonazepam {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Triazolam {u} (Compound) resembles {v} (Compound) Camazepam
Camazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Triazolam {u} (Compound) resembles {v} (Compound) Estazolam
Estazolam {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Triazolam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Flunitrazepam {u} (Compound) resembles {v} (Compound) Midazolam
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Triazolam {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Triazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Triazolam (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Triazolam (Compound) resembles Clonazepam (Compound) and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Triazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Triazolam (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Triazolam (Compound) resembles Clonazepam (Compound) and Clonazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Triazolam (Compound) resembles Camazepam (Compound) and Camazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Triazolam (Compound) resembles Estazolam (Compound) and Estazolam (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Triazolam (Compound) resembles Flunitrazepam (Compound) and Flunitrazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Triazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor